Retigabin (2) – Trobalt®
Epilepsy, focal seizures
Characteristics
| Start date | 01.05.2013 |
|---|---|
| Resolution | 15.08.2013 |
| INN | Retigabin |
| Brand name | Trobalt® |
| Pharm. company |
Dossier: GlaxoSmithKline GmbH & Co. KG
New distributor: kohlpharma GmbH |
| G-BA Procedure ID | D-060 |
| ATC code | N03AX21 Other antiepileptics (N03AX) |
| DDD | 0.9 g O |
| Therapeutic area | Nervous system diseases Epilepsy |
| Reason for procedure | not completed: discontinued |
| Regulatory status | authorisation withdrawn by manufacturer |
| Specialty | Patent/data protection expired |
Associated procedures
| Retigabin (3) | Trobalt® | GlaxoSmithKline GmbH & Co. KG | Epilepsy, focal seizures | 26,800–53,600 | 100% additional benefit not proven | |
| Retigabin (2) | Trobalt® | GlaxoSmithKline GmbH & Co. KG | Epilepsy, focal seizures | n.d. | discontinued | |
| Retigabin (1) | Trobalt® | GlaxoSmithKline GmbH & Co. KG | Epilepsy, focal seizures |
0
85,000–175,000 |
100% additional benefit not proven repealed |
<< List of all resolutions